August 20, 2014

Combination Treatment Tames HIV/HCV Coinfection

Written by

Michael Saag, MD, a professor of medicine at the University of Alabama at Birmingham and director of the UAB Center for AIDS Research, noted that the cost of the combination therapy renders it widely unaffordable. “The question [is] … how do we make HIV care the most cost effective? This is important in HIV as more drugs go generic, but it is applicable to all areas of medicine,” he said. “We can’t afford to prescribe in the absence of consideration of cost of care.”

Back to Top